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Atherosclerosis is a slow inflammatory process in arterial walls which is, as a part of 
cardiovascular diseases, the main source of morbidity and mortality in developed countries. 
However, searching for the possibilities of atherosclerosis treatment requires detailed 
knowledge of pathogenesis of the disease itself. The use of mouse models offers one of the 
possibilities of studying the pathogenesis of atherosclerosis, which enables a number of 
interventions that would not be acceptable in human medicine. By using the high content lipid 
diet, we are able to induce the changes of lipid spectrum in mice. Moreover, if a targeted 
genetic manipulation is used, one can reach considerably advanced plaques in a relatively 
short time period. It is also possible to interfere in the process of atherogenesis in mouse 
models by using some hypolipidemic drugs, for example from the statin group that were 
represented in our studies by atorvastatin. By observing the vessel’s reactivity to atorvastatin 
dosage, one can obtain another figure (besides the influence on the level of lipids), that may 
reveal some lipid-independent effects of statin, so-called pleiotropic effects, which are getting 
into the forefront especially over the last years. 
In the process of atherogenesis, there are relatively complex changes on the 
immunological, morphological and functional levels in the organism, accompanied by 
complex signaling between cells that are involved in the process. One of the significant roles 
in the process of atherogenesis is attributed to TGF-β cytokine and its signaling, which 
despite of the signs of atheroprotection has not still been clarified, including the role of TGF-β 
receptors that apparently play the key role in the process of atherogenesis. 
The role of endoglin (TGF-β receptor III, ENG) and its signaling in aorta in chosen 
mouse models of atherosclerosis, with the consideration to the levels of its serum form 
(cleaved from the tissue), was the key topic of papers in this summary dissertation thesis. The 
pertinent influence of atorvastatin on these processes was taken into account as well. Endoglin 
was described as a significant TGF-β receptor with the potential of atheroprotection, 
especially in terms of the influence on the production of eNOS and VEGF, in the 
atherosclerotic aorta in apoE/LDLR deficient mice. On the other hand, the serum form of this 
protein (sENG) was identified as a potentially negative marker of the atherosclerotic process. 
The study of atorvastatin effect in the apoE/LDLR deficient model revealed, besides the 
influence on serum lipids, the ability of non-lipid effect in terms of the size reduction of 
atherosclerotic plaques, the expression increase of potentially atheroprotective molecules of 
TGF-β signaling (ENG/ALK-5/Smad2/eNOS and ENG/ALK-1/Smad1/VEGF pathways) and 
the reduction of serum endoglin levels. 
The study of two mouse strains with a different predisposition to atherosclerosis 
(C57BL/6J vs. C3H/HeJ) proved a reduced aortic sensitivity in C3H/HeJ atheroprotective 
strain to the expression of inflammatory (adhesion) molecules P-selectin, VCAM-1, ICAM-1, 
and showed a possible endoglin participation in the increase of eNOS expression in the aorta 
of this strain, compared to C57BL/6J sensitive strain. 
The histological study with apoE-deficient mouse models evaluated the extra-cardiac 
part of aorta as a relevant one at studying atherosclerotic process, compared to the area of the 
aortic sinus, that does not reflect the changes of endoglin in the atherogenetic process and thus 
probably has a relation more likely to the cardiogenesis and heart valves development. We 
showed that endoglin is not co-localized with cell adhesion molecules (P-selectin and VCAM-
1) involved in atherosclerosis, suggesting it might not participate in leukocyte accumulation in 
aorta of apoE-deficient mice during atherogenesis. 
By summarizing the role of endoglin in atherogenesis in the review article, that also 
included the results of some above-mentioned studies, it is possible to deduce, that the role of 
TGF-β receptor III (ENG) in atherogenesis more likely appears as atheroprotective. On the 
other hand, the role of serum form of this protein (sENG) seems to be hopeful in terms of 
observing the levels as the marker of atherosclerotic process severity. However, the 
implementation of these conclusions into human medicine and its use e.g. in the context of the 
efficiency of statin therapy, still requires a search for deeper understanding. 
 
